Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy.
MDR-TB
adverse drug reactions
hematologic
linezolid
Journal
Journal of basic and clinical physiology and pharmacology
ISSN: 2191-0286
Titre abrégé: J Basic Clin Physiol Pharmacol
Pays: Germany
ID NLM: 9101750
Informations de publication
Date de publication:
25 Jun 2021
25 Jun 2021
Historique:
received:
29
11
2020
accepted:
07
04
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
16
2
2022
Statut:
epublish
Résumé
This study aimed to estimate the prevalence and analyze the risk factors for linezolid-induced hematological side effects in multidrug-resistant tuberculosis (MDR-TB) patients. Data were collected from medical records of MDR-TB patients who received linezolid between January 2018 and May 2020. Statistical significance analysis and multivariate analysis were performed with SPSS version 24 software. Hematological side effects were identified in 27 out of 93 patients (29.0%). The most prevalent effect was anemia (29.0%), while the less prevalent effects were thrombocytopenia (3.2%) and leukopenia (2.2%). These side effects were reported after 2 weeks of linezolid treatment. The drug dose was more than 11 mg/kgBW/day or patient weighing less than 54 kg was identified as an independent risk factor for anemia in multivariate analysis. Anemia was the most prevalent of linezolid-induced hematological side effects in MDR-TB patients. Therefore, hemoglobin monitoring might be recommended in patients weighing less than 54 kg and after receiving linezolid therapy for at least 2 weeks.
Identifiants
pubmed: 34214355
pii: jbcpp-2020-0468
doi: 10.1515/jbcpp-2020-0468
doi:
Substances chimiques
Acetamides
0
Antitubercular Agents
0
Oxazolidinones
0
Linezolid
ISQ9I6J12J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
777-781Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
Ferry, T, Batailler, C, Conrad, A, Triffault-Fillit, C, Laurent, F, Valour, F, et al.. Correction of linezolid-induced myelotoxicity after switch to tedizolid in a patient requiring suppressive antimicrobial therapy for multidrug resistant staphylococcus epidermidis prosthetic-joint infection. Open Forum Infect Dis 2018;5.
Lee, M, Lee, J, Carroll, MW, Choi, H, Min, S, Song, T, et al.. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J 2012;16:1508–18.
WHO. Treatment guidelines for drug-resistant tuberculosis - 2016 update. Geneva: World Health Organization; 2016.
Singh, B, Cocker, D, Ryan, H, Sloan, D. Linezolid for drug-resistant pulmonary tuberculosis (Review). Cochrane Library; 2019.
Kemenkes. Panduan Pelayanan Tuberkulosis Resisten Obat untuk Fasilitas Pelayanan Kesehatan, Kementrian Kesehatan Republik Indonesia dan Gerakan Masyarakat Hidup Sehat. Indonesia: Kemenkes; 2019.
Gerson, SL, Kaplan, SL, Bruss, JB, Le, V, Arellano, FM, Hafkin, B, et al.. Hematologic Effects of Linezolid: Summary of Clinical Experience. American Society for Microbiology; 2002:2723–6 pp.
Bernstein, WB, Richard, F, Trotta, RF, Rector, JT, Tjaden, JA, Barile, AJ. Mechanisms for linezolid-induced anemia and trombocytopenia. Ann Pharmacother 2003;37:517–20. https://doi.org/10.1345/aph.1c361.
Nishijo, N, Tsuji, Y, Matsunaga, K, Kutsukake, M, Okazaki, F, Fukumori, S, et al.. Mechanism underlying linezolid-induced thrombocytopenia in a chronic kidney failure mouse model. J Pharmacol Pharmacother 2017;1:8–13. https://doi.org/10.4103/jpp.JPP_167_16.
Cox, H, Ford, N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tubercul Lung Dis 2012;4:447–54. https://doi.org/10.5588/ijtld.11.0451.
Zhang, X, Falagas, ME, Vardakas, KZ, Wang, R, Qing, R, Wang, J, et al.. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis 2015;4:603–15. https://doi.org/10.3978/j.issn.2072-1439.2015.03.10.
Hanai, Y, Matsuo, K, Ogawa, M, Higashi, A, Kimura, I, Hirayama, S, et al.. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother 2016;22:536–42. https://doi.org/10.1016/j.jiac.2016.05.003.
Natsumoto, B, Yokota, K, Omata, F, Furukawa, K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Springerlink J 2014;42:1007–12. https://doi.org/10.1007/s15010-014-0674-5.
WHO. Global tuberculosis report 2019: executive summary. Geneva: WHO; 2019.
Tang, S, Yao, L, Hao, X, Zhang, X, Liu, G, Wu, M, et al.. Efficacy, safety and tolerability oflinezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015;1.
Ramachandran, G, Swaminathan, S. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf J 2015;3.
Busti, AJ. The mechanism for linezolid (zyvox) induced thrombocytopenia. EBM Consult 2015.
Alomar, MJ. Factors affecting the development of adverse drug reactions. Saudi Pharmaceut J 2014;22:83–94. https://doi.org/10.1016/j.jsps.2013.02.003.
Dryden, MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2011;6:7–15.
Nukui, Y, Hatakeyama, S, Okamoto, K, Yamamoto, T, Hisaka, A, Suzuki, H, et al.. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother 2013;68:2128–33. https://doi.org/10.1093/jac/dkt133.
Millard, J, Pertinez, H, Bonnett, L, Hodel, EM, Dartois, V, Johnson, JL, et al.. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta analysis and Monte Carlo simulation. J Antimicrob Chemother 2018;73:1–8. https://doi.org/10.1093/jac/dky096.